. Author manuscript; available in PMC: 2015 Aug 15.

Published in final edited form as: Biochem Pharmacol. 2014 Jun 14;90(4):367–378. doi: 10.1016/j.bcp.2014.06.006

Table 2.

Motesanib reverses the ABCG2-mediated drug resistance to mitoxantrone.

Treatment	NCI-H460		NCI-H460/MX20

	IC₅₀ ± SD^a (µM)	FR^b	IC₅₀ ± SD(µM)	FR
Mitoxantrone	0.012 ± 0.001	[1.0]	1.625 ± 0.102	[135.4]
+Motesanib (3 µM)	0.010 ± 0.001	[0.8]	0.564 ± 0.012^*	[47.0]
+FTC (3 µM)	0.007 ± 0.001	[0.6]	0.049 ± 0.004^*	[4.1]
Cisplatin	1.403 ± 0.028	[1.0]	1.347 ± 0.007	[1.0]
+Motesanib (3 µM)	1.383 ± 0.026	[1.0]	1.353 ± 0.051	[1.0]
+FTC (3 µM)	1.360 ± 0.082	[1.0]	1.327 ± 0.055	[0.9]

IC₅₀ values are represented as mean ± SD of at least three independent experiments performed in triplicate.

Values represent the resistance fold (RF) obtained by dividing IC₅₀ value of antineoplastic drugs in NCI-H460 and NCI-H460/MX20 cells with or without reversal agent divided by the IC₅₀ value of respective antineoplastic drug in NCI-H460 cells without reversal agent. Cell survival assay was determined by the MTT assay as described in Section 2. FTC was used as a positive control of ABCG2 inhibitor.

P < 0.01 versus the control group without reversal agent.